Cosopt PF (dorzolamide HCl 2%, timolol maleate 0.5% ophthalmic solution), the preservative-free formulation of Cosopt (contains benzalkonium chloride) has been made available by Merck.  This product was previously approved by the FDA on February 1, 2012.

Cosopt PF ophthalmic solution is a combination of a carbonic anhydrase inhibitor (sulfonamide) with a noncardioselective β-blocker indicated for the reduction of elevated intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension who are insufficiently responsive to β-blockers.

In an active-treatment controlled, parallel, double-masked study, Cosopt PF had an IOP-lowering effect equivalent to that of Cosopt in 261 patients with elevated IOP ≥22mmHg in one or both eyes. The IOP-lowering effect of Cosopt twice daily was greater (1–3mmHg) than that of monotherapy with either dorzolamide HCl 2% three times daily or timolol maleate 0.5% twice daily.

Cosopt PF is supplied in 0.2mL single-use containers.

For more information call (800) 672-6372 or visit